Avadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
Avadel Pharmaceuticals (Nasdaq: AVDL) announced its upcoming participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) announced its upcoming participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, May 20 at 12:00 p.m. ET. Investors can access both the live webcast and a 90-day archived recording of the presentation through Avadel's Investor Relations website at investors.avadel.com.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was -5.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 at 12:00 p.m. ET.
A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.